INCY
FY2026 Q1 · Calendar Q2 2026
Incyte Corporation
Incyte is executing a multi-franchise transition beyond its flagship Jakafi franchise, and Q1 2026 delivered the first proof point that the growth thesis is tracking. Revenue of $1.27B beat consensus by 4.7% and EPS beat by 35%, driven by broad-based growth across hematology, oncology, and immunology. Management reaffirmed full-year guidance of $4.77-$4.94B and detailed four product launches planned for 2026 — Jakafi XR, Opzelura in Europe, Monjuvi in first-line DLBCL, and povorcitinib for HS — backed by regulatory milestones including an ahead-of-schedule FDA NDA acceptance for povorcitinib. The pipeline is maturing rapidly, with pivotal readouts expected from the 989 CALR antibody, 734 KRAS G12D inhibitor, and A90 programs. The bullish score rose to 82 from 78 the prior quarter, and the stock posted a +2.6% abnormal return on the report day. The key question for investors is whether…
EPS surprise+35.1%
Market move+2.1%
